The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)
Filter results
| Date | Title | |
|---|---|---|
| 5/07/2019 | ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia | |
| 27/05/2019 | The López-Belmonte family increase their interest in ROVI to 63.1% | |
| 8/05/2019 | First quarter 2019 results press release | |
| 19/03/2019 | Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia | |
| 26/02/2019 | Full year 2018 results press release | |
| 15/02/2019 | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | |
| 9/01/2019 | ROVI acquires Falithrom® for the German market |